相似文献
1
Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Fourth Meeting: lessons learned from first clinical trials.
Transplantation. 2013 Aug 15;96(3):234-8. doi: 10.1097/TP.0b013e318298f9fa.
2
Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT).
Transplantation. 2010 Jul 27;90(2):124-6. doi: 10.1097/TP.0b013e3181ea4240.
3
Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group.
Transplantation. 2009 Sep 15;88(5):614-9. doi: 10.1097/TP.0b013e3181b4425a.
4
Mesenchymal stem cells: application for solid-organ transplantation.
Curr Opin Organ Transplant. 2012 Feb;17(1):55-62. doi: 10.1097/MOT.0b013e32834ee676.
5
Infusion of mesenchymal stromal cells after deceased liver transplantation: A phase I-II, open-label, clinical study.
J Hepatol. 2017 Jul;67(1):47-55. doi: 10.1016/j.jhep.2017.03.001. Epub 2017 Mar 9.
6
Japan's approval of stem-cell treatment for spinal-cord injury concerns scientists.
Nature. 2019 Jan;565(7741):544-545. doi: 10.1038/d41586-019-00178-x.
7
Caveats of mesenchymal stem cell therapy in solid organ transplantation.
Transpl Int. 2015 Jan;28(1):1-9. doi: 10.1111/tri.12415. Epub 2014 Sep 30.
8
First-in-Human Case Study: Multipotent Adult Progenitor Cells for Immunomodulation After Liver Transplantation.
Stem Cells Transl Med. 2015 Aug;4(8):899-904. doi: 10.5966/sctm.2015-0002. Epub 2015 Jun 3.
9
A Brief Analysis of Mesenchymal Stem Cells as Biological Drugs for the Treatment of Acute-on-Chronic Liver Failure (ACLF): Safety and Potency.
Curr Stem Cell Res Ther. 2020;15(3):202-210. doi: 10.2174/1574888X15666200101124317.
10
Potential of mesenchymal stem cells as immune therapy in solid-organ transplantation.
Transpl Int. 2009 Apr;22(4):365-76. doi: 10.1111/j.1432-2277.2008.00786.x. Epub 2008 Nov 1.
引用本文的文献
1
The issue of heterogeneity of MSC-based advanced therapy medicinal products-a review.
Front Cell Dev Biol. 2024 Jul 26;12:1400347. doi: 10.3389/fcell.2024.1400347. eCollection 2024.
2
Delivery of Mesenchymal Stem Cells during Hypothermic Machine Perfusion in a Translational Kidney Perfusion Study.
Int J Mol Sci. 2024 May 5;25(9):5038. doi: 10.3390/ijms25095038.
3
The Immunomodulatory Properties of Mesenchymal Stem Cells Play a Critical Role in Inducing Immune Tolerance after Liver Transplantation.
Stem Cells Int. 2021 Sep 4;2021:6930263. doi: 10.1155/2021/6930263. eCollection 2021.
4
Large Animal Models of Vascularized Composite Allotransplantation: A Review of Immune Strategies to Improve Allograft Outcomes.
Front Immunol. 2021 Jun 30;12:664577. doi: 10.3389/fimmu.2021.664577. eCollection 2021.
5
Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients with Acute Respiratory Distress Syndrome (ARDS).
CellR4 Repair Replace Regen Reprogram. 2020;8. doi: 10.32113/cellr4_20204_2839. Epub 2020 Apr 28.
6
Ex Vivo Mesenchymal Stem Cell Therapy to Regenerate Machine Perfused Organs.
Int J Mol Sci. 2021 May 15;22(10):5233. doi: 10.3390/ijms22105233.
7
Mesenchymal stromal cells for corneal transplantation: Literature review and suggestions for successful clinical trials.
Ocul Surf. 2021 Apr;20:185-194. doi: 10.1016/j.jtos.2021.02.002. Epub 2021 Feb 16.
8
Immunomodulatory Properties of Mesenchymal Stromal Cells Can Vary in Genetically Modified Rats.
Int J Mol Sci. 2021 Jan 25;22(3):1181. doi: 10.3390/ijms22031181.
9
The emergence of regenerative medicine in organ transplantation: 1st European Cell Therapy and Organ Regeneration Section meeting.
Transpl Int. 2020 Aug;33(8):833-840. doi: 10.1111/tri.13608. Epub 2020 Apr 28.
10
Therapeutic Mesenchymal Stromal Cells for Immunotherapy and for Gene and Drug Delivery.
Mol Ther Methods Clin Dev. 2020 Jan 22;16:204-224. doi: 10.1016/j.omtm.2020.01.005. eCollection 2020 Mar 13.
本文引用的文献
1
Bone marrow-derived mesenchymal stromal cells from patients with end-stage renal disease are suitable for autologous therapy.
Cytotherapy. 2013 Jun;15(6):663-72. doi: 10.1016/j.jcyt.2013.01.010. Epub 2013 Feb 16.
2
Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study.
Stem Cells Transl Med. 2013 Feb;2(2):107-11. doi: 10.5966/sctm.2012-0114. Epub 2013 Jan 24.
3
Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study.
Transplantation. 2013 Jan 15;95(1):161-8. doi: 10.1097/TP.0b013e3182754c53.
4
Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion.
Front Immunol. 2012 Sep 26;3:297. doi: 10.3389/fimmu.2012.00297. eCollection 2012.
5
Cell therapy medicinal product regulatory framework in Europe and its application for MSC-based therapy development.
Front Immunol. 2012 Aug 14;3:253. doi: 10.3389/fimmu.2012.00253. eCollection 2012.
6
Mesenchymal stromal cells: a key player in 'innate tolerance'?
Immunology. 2012 Nov;137(3):206-13. doi: 10.1111/j.1365-2567.2012.03621.x.
7
Mesenchymal stem cells derived from adipose tissue are not affected by renal disease.
Kidney Int. 2012 Oct;82(7):748-58. doi: 10.1038/ki.2012.187. Epub 2012 Jun 13.
8
Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial.
JAMA. 2012 Mar 21;307(11):1169-77. doi: 10.1001/jama.2012.316.
9
Multipotent mesenchymal stromal cell therapy and risk of malignancies.
Stem Cell Rev Rep. 2013 Feb;9(1):65-79. doi: 10.1007/s12015-011-9345-4.
10
Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation--a phase I study (MISOT-I).
J Transl Med. 2011 Jul 28;9:124. doi: 10.1186/1479-5876-9-124.
Zotero 插件